Results 161 to 170 of about 17,799 (195)
J Med Internet ResSome of the next articles are maybe not open access.
Related searches:
Related searches:
Drug Intelligence & Clinical Pharmacy, 1983
Ranitidine is a selective, competitive histamine H2-receptor antagonist recently approved by the Food and Drug Administration for use in the short-term treatment of active duodenal ulcers and gastric hypersecretory conditions. Ranitidine is four to ten times more potent than cimetidine on a molar basis in inhibiting stimulated gastric acid secretion ...
T S, Gaginella, J H, Bauman
openaire +2 more sources
Ranitidine is a selective, competitive histamine H2-receptor antagonist recently approved by the Food and Drug Administration for use in the short-term treatment of active duodenal ulcers and gastric hypersecretory conditions. Ranitidine is four to ten times more potent than cimetidine on a molar basis in inhibiting stimulated gastric acid secretion ...
T S, Gaginella, J H, Bauman
openaire +2 more sources
Headache: The Journal of Head and Face Pain, 1985
SYNOPSIS Five patients developed severe headaches in close association with the use of ranitidine. Two required hospitalization and three had recurrence of headaches on rechallenge. One had exacerbation of classic migraine. Headaches varied from intermittent and throbbing to steady and continuous, and onset was 12 hours to several ...
C M, Epstein, J, Klopper
openaire +2 more sources
SYNOPSIS Five patients developed severe headaches in close association with the use of ranitidine. Two required hospitalization and three had recurrence of headaches on rechallenge. One had exacerbation of classic migraine. Headaches varied from intermittent and throbbing to steady and continuous, and onset was 12 hours to several ...
C M, Epstein, J, Klopper
openaire +2 more sources
JAMA: The Journal of the American Medical Association, 1983
Ranitidine is an H2-receptor antagonist that was released recently for use in the treatment of acute duodenal ulcer disease, Zollinger-Ellison syndrome, and systemic mastocytosis with gastric hypersecretion. The pharmacokinetics, efficacy, adverse effects, and clinical utility of ranitidine are presented.
openaire +2 more sources
Ranitidine is an H2-receptor antagonist that was released recently for use in the treatment of acute duodenal ulcer disease, Zollinger-Ellison syndrome, and systemic mastocytosis with gastric hypersecretion. The pharmacokinetics, efficacy, adverse effects, and clinical utility of ranitidine are presented.
openaire +2 more sources